Description:
BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex. Potent helicase-primase inhibitor (HPI) effective against herpes simplex virus (HSV) infections with IC50 value of 20 nM for inhibition of the replication of both HSV-1 and HSV-2 in Vero cells, and ED50 value of 0.5 mg/kg for both HSV-1 and HSV-2 in the murine lethal challenge model of disseminated herpes.
- Molecular Weight:402.49
- Boiling Point:639.4±65.0 °C at 760 mmHg
- Purity:98%
Molecular Formula:
C18H18N4O3S2
Canonical SMILES:
CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N
InChI:
InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
InChIKey:
IVZKZONQVYTCKC-UHFFFAOYSA-N
Solubility:
In vitro: 10 mM in DMSO
Appearance:
White powder
Application:
For research used only
Storage: Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Synonyms:
Pritelivir; BAY-57-1293; BAY 57-1293; BAY-57 1293; BAY 57 1293; BAY571293; AIC316; AIC 316; AIC-316 Más detalles se encuentran
aquí